Xiao R et al., 2022-06-01: Cross-sectional study of 2021 hospital price-transparency files at 61 NCI-designated cancer centers (27 disclosed payer-specific prices): median markups over estimated 340B acquisition cost ran from 118.4% to 633.6%, with up to 15.8-fold price differences between centers.
Median drug price markups across all centers and payers ranged between 118.4% (sipuleucel-T) and 633.6% (leuprolide).
Abstract, RESULTS
Xiao R et al., 2022-06-01: Cross-sectional study of 2021 hospital price-transparency files at 61 NCI-designated cancer centers (27 disclosed payer-specific prices): median markups over estimated 340B acquisition cost ran from 118.4% to 633.6%, with up to 15.8-fold price differences between centers. Funding: Dr McWilliams reports Arnold Ventures grants 'during the conduct of the study'; other authors report outside grants and fees (Ross: FDA, J&J, NIH; Gross: NCCN/AstraZeneca, Genentech; Dusetzina: Commonwealth Fund, LLS, Arnold Ventures, RWJF, West Health, ICER, MedPAC). No study drug or maker; comparator is estimated 340B acquisition cost, not another treatment. CORRECTION: this is a 2022 JAMA Internal Medicine study, not a '2018 study in the Journal of Clinical Oncology' – the 118%-634% figures match, the journal and year do not (see CHE-13).
